Expression of HER2neu in Ductal Carcinoma in situ is Associated with Local Recurrence

Clinical Oncology

Volumn 24, Issue 3, 2012, Pages 183-189

  Han, K ^a,b   Nofech Mozes, S ^b   Narod, S ^b   Hanna, W ^b   Vesprini, D ^a,b   Saskin, R ^b   Taylor, C ^b   Kong, I ^a,b   Paszat, L ^a,b   Rakovitch, E ^a,b  

^a UNIVERSITY OF TORONTO   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

Author keywords

Ductal carcinoma in situ; HER2neu; Immunohistochemical staining; Local recurrence

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR;

ADULT; AGED; ARTICLE; CANCER INVASION; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER RISK; CANCER SURGERY; CONTROLLED STUDY; FEMALE; FOLLOW UP; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INTRADUCTAL CARCINOMA; MAJOR CLINICAL STUDY; MEDICAL RECORD REVIEW; MULTIMODALITY CANCER THERAPY; PARTIAL MASTECTOMY; PHENOTYPE; PREDICTIVE VALUE; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR VOLUME;

ADULT; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CARCINOMA, INTRADUCTAL, NONINFILTRATING; FEMALE; HUMANS; MASTECTOMY, SEGMENTAL; MIDDLE AGED; NEOPLASM INVASIVENESS; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PROGNOSIS; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL;

EID: 84857923923     PISSN: 09366555     EISSN: 14332981     Source Type: Journal    
DOI: 10.1016/j.clon.2011.09.008     Document Type: Article

References (25)

1. Ernster V.L., Ballard-Barbash R., Barlow W.E., et al. Detection of ductal carcinoma in situ in women undergoing screening mammography. J Natl Cancer Inst 2002, 94:1546-1554.
2. Bijker N., Peterse J.L., Duchateau L., et al. Risk factors for recurrence and metastasis after breast-conserving therapy for ductal carcinoma-in-situ: analysis of European organization for research and treatment of cancer trial 10853. J Clin Oncol 2001, 19:2263-2271.
3. Fisher E.R., Dignam J., Tan-Chiu E., et al. Pathologic findings from the national surgical adjuvant breast project (NSABP) eight-year update of protocol B-17: intraductal carcinoma. Cancer 1999, 86:429-438.
4. Kerlikowske K., Molinaro A., Cha I., et al. Characteristics associated with recurrence among women with ductal carcinoma in situ treated by lumpectomy. J Natl Cancer Inst 2003, 95:1692-1702.
5. Perou C.M., Sorlie T., Eisen M.B., et al. Molecular portraits of human breast tumours. Nature 2000, 406:747-752.
6. Sorlie T., Perou C.M., Tibshirani R., et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA 2001, 98:10869-10874.
7. van't Veer L.J., Dai H., Vijver M.J., et al. Gene expression profiling predicts clinical outcome of breast cancer. Nature 2002, 415:530-536.
8. Sorlie T., Tibshirani R., Parker J., et al. Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci USA 2003, 100:8418-8423.
9. Sotiriou C., Neo S.Y., McShane L.M., et al. Breast cancer classification and prognosis based on gene expression profiles from a population-based study. Proc Natl Acad Sci USA 2003, 100:10393-10398.
10. Carey L.A., Perou C.M., Livasy C.A., et al. Race, breast cancer subtypes, and survival in the Carolina breast cancer study. JAMA 2006, 295:2492-2502.
11. Nielsen T.O., Hsu F.D., Jensen K., et al. Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma. Clin Cancer Res 2004, 10:5367-5374.
12. Brenton J.D., Carey L.A., Ahmed A.A., et al. Molecular classification and molecular forecasting of breast cancer: ready for clinical application?. J Clin Oncol 2005, 23:7350-7360.
13. Bryan B.B., Schnitt S.J., Collins L.C. Ductal carcinoma in situ with basal-like phenotype: a possible precursor to invasive basal-like breast cancer. Mod Pathol 2006, 19:617-621.
14. Kepple J., Henry-Tillman R.S., Klimberg V.S., et al. The receptor expression pattern in ductal carcinoma in situ predicts recurrence. Am J Surg 2006, 192:68-71.
15. Livasy C.A., Perou C.M., Karaca G., et al. Identification of a basal-like subtype of breast ductal carcinoma in situ. Hum Pathol 2007, 38:197-204.
16. Meijnen P., Peterse J.L., Antonini N., et al. Immunohistochemical categorisation of ductal carcinoma in situ of the breast. Br J Cancer 2007, 98:137-142.
17. Tamimi R., Baer H., Marotti J., et al. Comparison of molecular phenotypes of ductal carcinoma in situ and invasive breast cancer. Breast Cancer Res 2008, 10:R67.
18. Hannemann J., Velds A., Halfwerk J.B., et al. Classification of ductal carcinoma in situ by gene expression profiling. Breast Cancer Res 2006, 8:R61.
19. Allred D.C., Wu Y., Mao S., et al. Ductal carcinoma in situ and the emergence of diversity during breast cancer evolution. Clin Cancer Res 2008, 14:370-378.
20. Rosen P.P. Rosen's breast pathology 2001, Lippincott Williams & Wilkins, Philadelphia.
21. Holland R., Peterse J.L., Millis J.R., et al. Ductal carcinoma in situ: a proposal for a new classification. Semin Diagn Pathol 1994, 11:167-180.
22. Rakovitch E., Pignol J.P., Hanna W., et al. The management of ductal carcinoma in situ of the breast: a screened population-based analysis. Breast Cancer Res Treat 2007, 101:335-347.
23. Baxter N., Virnig B.A., Durham S.B., et al. Trends in the treatment of ductal carcinoma in situ of the breast. J Natl Cancer Inst 2004, 6:443-448.
24. Kerlikowske K., Molinaro A.M., Gauthier M.L., et al. Biomarker expression and risk of subsequent tumors after initial ductal carcinoma in situ diagnosis. J Natl Cancer Inst 2010, 102:627-637.
25. Morrow M., O'Sullivan M.J. The dilemma of DCIS. Breast 2007, 16:S59-S62.